BNORMALLY elevated cerebral blood flow (CBF), or "hyperemia," has been observed relatively frequently after traumatic brain injury. 11, 15, 30, 32, 33, 35, 37 However, despite numerous investigations on the subject, a consensus has not been reached on its pathophysiological origins and clinical impact. Specifically, the effect of hyperemia on neurological outcome after head injury remains poorly defined. Whereas some investigators have shown elevated blood flow to be associated with improved outcome, others have found no such correlation. 15, 30, 35, 37 The relationship between CBF and intracranial hypertension after head injury is equally unclear.
ߜ The role of posttraumatic hyperemia in the development of raised intracranial pressure (ICP) has important pathophysiological and therapeutic implications. To determine the relationship between hyperemia (cerebral blood flow (CBF) Ͼ 55 ml/100 g/minute), intracranial hypertension (ICP Ͼ 20 mm Hg), and neurological outcome, 193 simultaneous measurements of ICP and CBF (xenon-133 method) were obtained in 59 patients with moderate and severe head injury.
Hyperemia was associated with an increased incidence of simultaneous intracranial hypertension compared to nonhyperemic CBF measurements (32.2% vs. 21.6%, respectively; p Ͻ 0.059). However, in 78% of blood flow studies in which ICP was greater than 20 mm Hg, CBF was less than or equal to 55 ml/100 g/minute. At least one episode of hyperemia was documented in 34% of patients, all of whom had a Glasgow Coma Scale (GCS) score of 9 or below. In 12 individuals with hyperemia without simultaneous intracranial hypertension, ICP was greater than 20 mm Hg for an average of 11 Ϯ 16 hours and favorable outcomes were seen in 75% of patients. In contrast, in eight individuals with hyperemia and at least one episode of hyperemia-associated intracranial hypertension, ICP was greater than 20 mm Hg for an average of 148 Ϯ 84 hours (p Ͻ 0.001), and a favorable outcome was seen in only one patient (p Ͻ 0.001). Compared to the remainder of the cohort, patients with hyperemia-associated intracranial hypertension were distinctive in being the youngest, exhibiting the lowest GCS scores (all ≤ 6), and having the highest incidence of effaced basilar cisterns and intractable intracranial hypertension.
In the majority of individuals with hyperemia-associated intracranial hypertension, their clinical profile suggests the occurrence of a severe initial insult with resultant gross impairment of metabolic vasoreactivity and pressure autoregulation. In a minority of these patients, however, high CBF may be coupled to a hypermetabolic state, given their responsiveness to metabolic suppressive therapy. In patients with hyperemia but without intracranial hypertension, elevated CBF is also likely to be a manifestation of appropriate coupling to increased metabolic demand consistent with a generally favorable outcome. This study supports the concept that there are multiple etiologies of both elevated blood flow and intracranial hypertension after head injury.
nial hypertension by passive increases in blood flow. Clearly it would be useful to identify patients in whom hyperemia is a primary factor in the genesis of elevated ICP so that therapy could be appropriately modified.
Given these unresolved issues surrounding posttraumatic hyperemia, the purpose of this investigation was to determine the relationship between global CBF, intracranial hypertension, and outcome in head-injured patients treated with current methods of CPP-and ICP-based management. Specific goals of the study included: 1) documenting the incidence, time course, and clinical determinants of hyperemia that occurred with and without associated intracranial hypertension; 2) determining if vasopressor therapy is linked to an increased risk of hyperemia-associated intracranial hypertension; and 3) defining the impact on long-term neurological outcome of hyperemia occurring with and without intracranial hypertension. To achieve these objectives, data analysis was performed on individual CBF studies and on individual patients with hyperemia as categorized by simultaneously recorded CBF and ICP measurements.
Clinical Material and Methods

Patient Enrollment
Between July 1992 and January 1995, 184 patients with acute head injuries were prospectively enrolled in the University of California at Los Angeles (UCLA) Brain Injury Research Center Program and treated at either the UCLA or Harbor-UCLA Medical Centers. Informed consent was obtained from family members of all participants in the study. Of the original cohort, 67 patients had sustained a moderate or severe head injury with postresuscitation Glasgow Coma Scale (GCS) scores of 13 or less and underwent serial CBF measurements during their stay in the intensive care unit. Within this group, 59 patients underwent simultaneous ICP recordings at the time of their blood flow study, and they are the focus of this report.
Determination of Cerebral Blood Flow
The CBF was measured by the xenon-133 intravenous technique of Obrist, et al., 33 using a bedside cerebrograph instrument with five external collimators placed over each hemisphere (Ceretronix Cerebrograph Cortexplorer model 10; Laco, Inc., Chesterfield, OH). At the time of the CBF measurement, patients' ICP, CPP, and PaCO 2 were recorded (CPP was defined as the difference between the mean arterial blood pressure and the ICP). Concurrently administered vasopressors (dopamine, phenylephrine, or norepinephrine) and metabolic suppressive agents (high-dose pentobarbital or propofol) were also documented. As previously described, 26 the CBF 15 was determined for each cerebral hemisphere, and global CBF was defined as the average of the two hemispheric rates and expressed in milliliters/100 g/minute. Hyperemia was defined as a global CBF 15 of greater than 55 ml/100 g/ minute, which is two standard deviations (SD) above normal (44.1 Ϯ 5.6 ml/100 g/minute) when adjusted for a PaCO 2 of 34 mm Hg. 32 Individual CBF values were not adjusted to a normative PaCO 2 to define more accurately the relationship of actual CBF to ICP and because mild hyperventilation was routinely used. Additionally, given the marked variability in both global and regional PaCO 2 reactivity after head injury, performing this PaCO 2 adjustment on individual CBF studies is of questionable validity. 11, 22, 30 
Arteriovenous Difference of Oxygen
In a subset of 19 patients, jugular bulb catheters were placed and multiple daily determinations of arteriovenous difference of oxygen (AVDO 2 ) were obtained. Catheters were placed in standard fashion via retrograde cannulation of an internal jugular vein, typically on the right side, and proper placement was confirmed with a lateral cervical radiograph. The AVDO 2 was determined by taking the difference in O 2 content of simultaneously obtained arterial and jugular venous blood samples, using the following formula: 1.34 ϫ hemoglobin concentration ϫ O 2 saturation. Normal AVDO 2 is 6.7 ml/dl, with a range of 4.5 to 8.5 ml/dl. 34 Only AVDO 2 measurements taken on days on which CBF studies were performed were analyzed in this report. All values for a given day were averaged for that day for each patient.
Recording of ICP and CPP
The ICP was measured via ventricular catheter in 53 patients and via parenchymal transducer in six. Intracranial hypertension was defined as an ICP of greater than 20 mm Hg sustained for more than 5 minutes. In addition to recording ICP and CPP at the time of CBF determination, these readings were also recorded on an hourly (endhour) basis, as was previously performed in the Traumatic Coma Data Bank cohort. 25 
Categorization of Studies and Patients by CBF and ICP
Individual 133
Xe-CBF studies were categorized as one of four types based on CBF and simultaneously recorded ICP: 1) CBF greater than 55 ml/100 g/minute and ICP greater than 20 mm Hg (Type A studies); 2) CBF greater than 55 ml/100 g/minute and ICP less than or equal to 20 mm Hg (Type B studies); 3) CBF less than or equal to 55 ml/100 g/minute and ICP greater than 20 mm Hg (Type C studies); and 4) CBF less than or equal to 55 ml/100 g/minute and ICP less than or equal to 20 mm Hg (Type D studies). Patients were then divided into four groups based on CBF type: Group 1, those with at least one Type A CBF study; Group 2, those with no Type A but at least one Type B CBF study; Group 3, those with no Type A or B but at least one Type C study; Group 4, those with all Type D studies (Table 1) . To ascertain whether episodic ICP and CPP recorded at the time of CBF measurement were reflective of overall ICP and CPP course, patients were also assessed by group regarding average hourly ICP and CPP, mean maximum ICP, mean minimum CPP, and the average number of hours that ICP was greater than 20 mm Hg and CPP was less than 70 mm Hg.
Other Predictors of Outcome
Additional prognostic indicators were also documented. Systemic hypotension (systolic blood pressure Ͻ 90 mm Hg) or an abnormal pupillary response (poorly reactive or with an asymmetry of 2 mm or greater) were recorded from the initial prehospital setting through the first 24 hours of hospitalization. In addition, the first two comput-erized tomography (CT) scans obtained in each patient were analyzed for the presence of known predictors of poor outcome. 10, 13, 41 These indicators included perimesencephalic (basilar) cistern effacement (compressed or absent), diffuse swelling, diffuse swelling with midline shift of more than 4 mm, diffuse injury with punctate hemorrhages, subarachnoid hemorrhage (SAH), evacuated mass lesions (epidural, subdural, or intracerebral hematomas), multiple contusions, and gunshot wounds. An Injury Severity Score was also calculated for each patient. 2 Neurological outcome was determined at 6 months postinjury by the Glasgow Outcome Scale (GOS) 16 with favorable outcome defined as good recovery or moderate disability.
Patient Management
All patients were managed in the intensive care unit after initial stabilization in the emergency department or after craniotomy for evacuation of intracranial hematoma. Subsequent therapeutic goals included maintenance of ICP at less than 20 mm Hg and CPP at greater than 70 mm Hg. The ICP therapy was implemented in a stepwise fashion and entailed head elevation to 30˚ and mild hyperventilation (PaCO 2 30-35 mm Hg) followed by ventricular cerebrospinal fluid (CSF) drainage, narcotic sedation, neuromuscular blockade, and bolus mannitol therapy as needed. The CPP was maintained at 70 mm Hg or above with the use of intravascular volume expansion and vasopressor therapy. High-dose pentobarbital or propofol was used in select cases for intractable intracranial hypertension, defined as an ICP greater than 30 mm Hg persisting for more than 30 minutes and refractory to conventional methods. Infusion rates were titrated to achieve electroencephalographic burst-suppression periods of 6 to 12 seconds.
Statistical Analysis
Between-group analysis of continuous variables was performed using Student's t-test for comparison of two groups or by analysis of variance (ANOVA) for comparison of more than two groups. Multiple comparisons were not adjusted for an inflated alpha because the level of significance for individual comparisons was so high (typically p Ͻ 0.001). For those comparisons using ANOVA, simple main effects were compared using appropriate post hoc contrasts. Percentage comparisons were performed using a Bernoulli process. The Mann-Whitney U-test was used to assess differences in the median GCS score and the median number of CT diagnoses. All variances were expressed as SD.
Results
Patient Characteristics
The study cohort of 59 patients (49 male and 10 female) ranged in age from 16 to 80 years, with a mean age (Ϯ SD) of 33.8 Ϯ 16.5 years. Initial postresuscitation GCS scores ranged from 3 to 13; 52 patients (88.1%) had an initial GCS score of 8 or less. Closed head injuries occurred in 55 patients and gunshot wounds in four. Eleven patients (18.6%) sustained a hypotensive episode in the prehospital setting or within 24 hours of admission, and 26 (44.1%) had documentation of an abnormal pupillary response during this period. Twenty-three patients (39%) underwent craniotomy for evacuation of an epidural (eight), subdural (11), or intracerebral hematoma (five), including one patient who underwent evacuation of a subdural and an intracerebral hematoma. Nine patients (15.3%) were treated with high-dose pentobarbital (eight patients) or propofol (one patient) for intractable intracranial hypertension (Table 2) .
Hyperemia Studies
A total of 193 133
Xe studies were performed for a median of three studies per patient (range 1-10). Studies were performed from the day of injury (Day 0) through Day 14 postinjury with 72.5% of studies performed within the first 6 days postinjury (Days 0-5). The number of studies performed by postinjury day is shown in Fig. 1 . Hyperemia (CBF Ͼ 55 ml/100 g/minute) was recorded in CBF studies. The median duration of hyperemia in patients with hyperemia-associated intracranial hypertension (Group 1) was 6 days (range 1-14 days), whereas in those with hyperemia without intracranial hypertension (Group 2) the duration was 2.5 days (range 0-5 days postinjury) (p Ͻ 0.05).
Of patients with at least one hyperemic CBF study, 85% were younger than 35 years of age compared to 53.8% of those without hyperemia (p Ͻ 0.01); the mean age of the two groups was 28.4 versus 36.6 years, respectively (p Ͻ 0.07). Patients with hyperemia also tended to be more severely injured than those without (median postresuscitation GCS score of 5 vs. 6, respectively; p Ͻ 0.2). As expected, the mean CBF was significantly higher in patients with hyperemia compared to those without (49 Ϯ 9.3 ml/100 g/minute vs. 35.9 Ϯ 8.5 ml/100 g/minute; p Ͻ 0.001), whereas the mean PaCO 2 at the time of CBF determination was similar (33. 2 Ϯ 4.6 mm Hg vs. 33.2 Ϯ 5.7 mm Hg, respectively). The AVDO 2 was also significantly lower in hyperemic patients. Of the 19 patients with a jugular bulb catheter in place, six exhibited hyperemia by CBF criteria and had an average AVDO 2 of 2.64 Ϯ 0.62 ml/dl (30 determinations). In the 13 patients without hyperemia, the AVDO 2 averaged 4.87 Ϯ 1.63 ml/dl (52 determinations), at p Ͻ 0.0001 (Table 3) .
Hyperemia-Associated Intracranial Hypertension
Intracranial hypertension was documented simultaneously with hyperemia (Type A studies) in 10 (32.2%) of 31 hyperemic CBF studies compared to 35 (21.6%) of 162 nonhyperemic CBF studies (p Ͻ 0.059). These 10 studies in eight patients (13.6% of the patient cohort) were performed on Days 1 to 5 postinjury in seven cases and on Days 8, 9, or 10 in three cases. However, of the 45 instances of intracranial hypertension recorded at the time of the 133 Xe study, simultaneous hyperemia occurred in only 22.2%, whereas nonhyperemic blood flows were recorded in 77.8% (p Ͻ 0.001; Fig. 2 ).
Use of Vasopressor Agents in Relation to CBF, ICP, and CPP
At the time of CBF determination, 62 (32.1%) of 193 studies were performed when the patient was receiving a vasopressor agent. Blood flow studies performed on patients receiving vasopressors compared to those performed on patients not receiving vasopressors had a mean CBF of 43 Ϯ 18.2 ml/100 g/minute versus 39 Ϯ 12. 15 and simultaneously recorded intracranial pressure (ICP) in 193 studies performed in 59 patients. A, B, C, and D refer to CBF study type as defined in the text. The three Type D studies with the lowest CBFs and favorable outcome (asterisks) were obtained from the patient in Case 4 (Group 1) while this patient was being treated with high-dose pentobarbital therapy. This patient's Type A study, which was performed while pentobarbital therapy was discontinued, is identified by an arrow (see Table 6 ).
were as follows: Type A (hyperemia with intracranial hypertension), nine (90%) of 10; Type B (hyperemia without intracranial hypertension), six (28.6%) of 21; Type C (no hyperemia with intracranial hypertension), 13 (37.1%) of 35; and Type D (no hyperemia and no intracranial hypertension), 34 (26.8%) of 127. Thus, studies demonstrating hyperemia and simultaneous intracranial hypertension were more likely to be performed in the setting of vasopressor therapy than were studies of any other type (p Ͻ 0.001; Table 4 ).
Predictors of Outcome by Patient Group
Clinical predictors of outcome and physiological data regarding CBF, ICP, and CPP are summarized by group in Table 5 . A brief clinical synopsis is also provided below for each patient group.
Group 1 (Hyperemia With Intracranial Hypertension).
These eight individuals were young adults (≤ 30 years of age), except for one man who was 55 years old. The mean age was 25.6 Ϯ 12.5 years, and postresuscitation GCS scores ranged from 3 to 6. Three individuals had hypotensive insults. Seven patients showed diffuse swelling on initial CT scans, seven had compressed or absent basilar cisterns, six had midline shifts of greater than or equal to 4 mm, five had SAH, three had extraaxial hematomas requiring evacuation, and two sustained gunshot wounds to the head. Six patients were treated with high-dose pentobarbital and one was treated with propofol for intractable intracranial hypertension. Of the 10 CBF studies obtained in patients with hyperemia and ICP greater than 20 mm Hg, four were performed while patients were receiving pentobarbital and one was obtained while the patient was receiving propofol. Additionally, all five CBF studies from the entire cohort that demonstrated hyperemia after Day 5 postinjury were performed in four patients from this group (Table 6) .
Only one patient made a good recovery (Case 4 in Table  6 ). Although his CT scan showed a thin rim subdural hematoma and a focal contusion, he was unique in this group in having only one major CT diagnosis (diffuse swelling) and was the only individual without effaced cisterns. Additionally, he had a relatively rapid clinical improvement from an initial GCS score of 6 to a score of 10 over the first 24 hours after admission, with intermittent following of commands. He subsequently deteriorated, exhibiting progressively worsening intracranial hypertension that was refractory to conventional therapy. He was ultimately treated with pentobarbital for 5 days. On initiation of pentobarbital therapy, global CBF observed on xenon-enhanced CT was reduced from 77 ml/100 g/minute to 31 ml/100 g/minute, and ICP decreased from a range of 25 to 45 mm Hg to 15 to 25 mm Hg. Fluorodeoxyglucose positron emission tomography (PET) performed with the patient in a pentobarbital coma revealed a mean local cerebral metabolic rate for glucose of 2 mg/100 g/minute; the normal rate is 7 mg/100 g/minute. 4 
Group 2 (Hyperemia Without Intracranial Hypertension).
The mean age of these 12 patients was 30.2 Ϯ 18.2 years, and their initial GCS scores ranged from 4 to 9. Two individuals sustained hypotensive insults. Six patients presented with diffuse swelling on initial CT scanning, four had effaced basilar cisterns, four had midline shift, eight had SAH, four had evacuated intracranial hematomas, and eight had multiple contusions. No patient received metabolic suppressive therapy.
Group 3 (Intracranial Hypertension Without Hyperemia).
The mean age of these 12 patients was 35.8 Ϯ 11.3 years, and their initial GCS scores ranged from 3 to 13. Two sustained hypotensive insults. Nine patients presented with diffuse swelling on initial CT scanning, six had effaced basilar cisterns, six exhibited midline shift, nine had SAH, six had evacuated hematomas, 10 developed multiple contusions, and one had sustained a gunshot wound. One patient was treated with high-dose pentobarbital and died.
Group 4 (No Hyperemia and no Intracranial Hypertension).
The mean age of these 27 patients was 37 Ϯ 18.3 years, and their initial GCS scores ranged from 3 to 13. Four individuals sustained a hypotensive insult. Seventeen patients presented with diffuse swelling on initial CT scanning, 13 had effaced basilar cisterns, nine exhibited midline shift, 15 had SAH, 11 had evacuated intracranial hematomas, nine had multiple contusions, and one patient had sustained a gunshot wound. One patient was treated with high-dose pentobarbital and remained severely disabled.
Relative Differences in Clinical Predictors of Outcome, CBF, ICP, and CPP
Groups 1 through 4 did not differ significantly in terms of mean age, initial GCS score, median number of CT diagnoses, incidence of evacuated hematomas, abnormal pupils, hypotension, or mean injury severity score. However, the percentage of patients younger than 35 years of age was higher in Groups 1 and 2 than in Groups 3 and 4 (p Ͻ 0.05). Groups 1 and 2 also displayed significantly higher mean CBFs than Groups 3 and 4 (p Ͻ 0.001). Group 1 was distinctive in having the highest incidence of patients with compressed or absent perimesencephalic cisterns on CT evaluation compared to all other groups (p Ͻ 0.05) and had a higher incidence of diffuse swelling on CT scanning compared to Groups 2 and 4 (p Ͻ 0.05). Additionally, Group 1 had the highest incidence of intractable intracranial hypertension treated with metabolic suppressive therapy (p Ͻ 0.001). There were no significant differences in mean CPP between the groups. However, the mean ICP, hours that ICP was higher than 20 mm Hg, and average maximum ICP were significantly different between all groups (p Ͻ 0.001), except between Groups 1 and 3 and between Groups 2 and 4. The number D. F. Kelly, et al. of hours in which CPP was less than 70 mm Hg and the average minimum CPP were also significantly different between all groups (p Ͻ 0.05), except between Groups 2 and 4.
Posttreatment Outcome
For the cohort overall, recovery according to the GOS at 6 months postinjury was as follows: 13 (22%) with good recovery; 11 (18.6%) with moderate disability; 12 (20.3%) with severe disability; four patients (6.8%) vegetative; and 19 (32.2%) dead. Of the 20 patients with hyperemia (Groups 1 and 2), 10 achieved a favorable outcome, which was defined as good recovery or moderate disability. Of the eight patients with hyperemia-associated intracranial hypertension (Group 1), only one achieved a favorable outcome. In contrast, in the 12 patients with hyperemia without intracranial hypertension (Group 2), nine achieved a favorable outcome (p Ͻ 0.001). In the 39 patients with no recorded hyperemic CBF studies (Groups 3 and 4), 14 (35.9%) had a favorable outcome. Of those patients without hyperemia but with simultaneous intracranial hypertension (Group 3), a favorable outcome was seen in 50% of patients. In those without hyperemia and normal ICP (Group 4), favorable outcome occurred in 29.6%. Overall, patients with hyperemia without simultaneous intracranial hypertension fared significantly better than all other groups, whereas those with hyperemia-associated intracranial hypertension had significantly worse outcomes (p Ͻ 0.05).
Discussion
Summary of Results
In this cohort of 59 patients with moderate and severe head injury, at least one episode of hyperemia was documented in 34% of individuals, more often in younger patients and only in those with a GCS score of 9 or less. Hyperemia was seen most frequently during Days 1 to 5 postinjury and was an unusual finding on the day of injury. However, in patients with simultaneous hyperemia and intracranial hypertension, the duration of elevated blood flow was significantly more prolonged, and lasted up to 14 days. At the time of CBF measurement, the occurrence of hyperemia was not related to an elevated PaCO 2 , but
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Hyperemia after traumatic brain injury 767 was associated with an increased incidence of intracranial hypertension approaching statistical significance. However, in 78% of blood flow studies in which ICP was greater than 20 mm Hg, CBF was less than or equal to 55 ml/100 g/minute. Regarding long-term recovery, in patients with hyperemia without simultaneous intracranial hypertension, a favorable outcome occurred in 75%, whereas in those with hyperemia-associated intracranial hypertension, a favorable outcome occurred in only 12.5%. Compared to the remainder of the cohort, patients with hyperemia-associated intracranial hypertension were distinguished by being the youngest, having the lowest GCS scores, the highest incidence of effaced basilar cisterns and diffuse swelling on CT scans, and the most severe degree of intracranial hypertension and reduced CPP.
Defining Hyperemia
Because a major goal of this study was to determine if abnormally elevated blood flow was related to intracranial hypertension, a definition of hyperemia was used that had a high probability of being truly excessive relative to metabolic demand and was likely to be an important factor in the development of raised ICP. Obrist and colleagues 32, 33 originally defined relative and absolute hyperemia after severe head injury as "normal or supranormal blood flow in the presence of coma" based on the consistent findings of significantly narrowed AVDO 2 values and of depressed cerebral metabolic rates of oxygen to approximately 50% of normal. However, an assessment of glycolytic metabolism has been lacking from these and subsequent studies. 15, 30, 32, 33, 35 Recent experimental and clinical studies indicate that although oxidative metabolism remains markedly depressed after head injury, glycolysis increases dramatically in response to increased energy demand for reestablishing membrane ionic homeostasis. 3, 4, 14, 17, 18, 20, 43 This finding of regional or global hyperglycolysis has been observed in nine of 16 severely head injured patients treated at UCLA who underwent fluorodeoxyglucose PET within 7 days of injury, despite being comatose (manuscript in preparation). Six of these seven patients underwent CBF measurement within 24 hours of PET and blood flows were in the relative or absolute hyperemia range. 33 These data indicate that in many head-injured patients elevated CBF may be due to an increase in demand for glucose metabolism and therefore does not represent classic hyperemia.
An additional consideration in defining hyperemia is that under normal conditions a CBF of 50 to 55 ml/100 g/minute is associated with an ICP of 10 mm Hg or less. It may be reasonable to assume that after significant head injury, an above-normal CBF would contribute significantly to elevated ICP, given that brain edema, mass lesions, and possibly increases in cerebral blood volume will also promote intracranial hypertension in this setting. 5, 24, 29 For these reasons, a CBF of greater than 55 ml/100 g/minute, or absolute hyperemia as defined by Obrist, et al., 33 was chosen as the threshold for hyperemia. Although AVDO 2 values were obtained in only a minority of individuals in this study, the uniformly low values in patients with hyperemia by CBF criteria are consistent with global hyperemia relative to oxidative metabolism.
Previous Investigations
Earlier studies addressing the relationship between CBF and ICP after head injury have yielded results that are generally inconclusive. In 1974 Fieschi, et al., 11 noted simultaneous CBF greater than 55 ml/100 g/minute and ICP greater than 20 mm Hg in two of 12 patients, both of whom died a "cerebral death" attributed to "vasoparaly- 33 also suggested that hyperemia might be a significant factor in many instances of posttraumatic intracranial hypertension. However, in the study by Bruce, et al., in which diffuse swelling was seen on CT scanning in 63 pediatric patients with head injuries, an elevated CBF was documented in only six individuals. In the work by Obrist, et al., "relative hyperemia" (CBF between 32.9 and 55.3 ml/100 g/minute) or "absolute hyperemia" was seen in 35% and 20%, respectively, of 75 patients with severe head injuries, and there was a significant majority of patients with intracranial hypertension who also had hyperemia. However, in both of these reports ICP at the time of the CBF study and long-term outcome were not documented. More recently, studies by Muizelaar, et al., 30 and by Robertson, et al., 35 failed to find a correlation between elevated CBF and intracranial hypertension. Muizelaar, et al., in studying 32 children with head injuries, concluded that no relationship existed between hyperemia (CBF greater than or equal to 32.9 ml/100 g/minute) and simultaneously recorded ICP because the definition of hyperemia was "too generous." 30 Robertson, et al., in analyzing 102 severely injured patients, also found no correlation between normal or high CBF and elevated ICP; however, simultaneous CBF and ICP measurements were not performed in this study.
Physiological Stratification of Head-Injured Patients Based on CBF and ICP Measurements
Unlike previous studies, in the present investigation patients were categorized based on concurrent recordings of CBF and ICP. The validity of this method is supported by the fact that ICP recordings obtained at the time of CBF determination correlated extremely well with the cumulative (hourly) ICP values for each patient group. By using this approach, it becomes possible to postulate the existence of five subgroups of patients, each exhibiting relatively unique clinical courses and outcomes.
Hyperemia Without Intracranial Hypertension. In those patients (Group 2) who exhibited a relatively brief and early period of elevated CBF, the high rate of functional recovery was likely related to the low incidence of basilar cistern effacement, infrequent occurrence of hypotension, and minimal degree and duration of elevated ICP and reduced CPP. It is also postulated that hyperemia in these patients was at least partially attributable to appropriate coupling between blood flow and a relative degree of hypermetabolism. 3, 20, 37, 38, 43 The presence of intact metabolic vasoreactivity would also be consistent with a less severe intracranial insult and a higher likelihood of functional recovery. 27, 31 In this group CPP therapy and standard ICP control measures appear generally effective, presumably by optimizing pressure autoregulation and thereby allowing CBF to respond appropriately to metabolic demands. 7, 36 Hyperemia With Intracranial Hypertension and Favorable Outcome. Although only one individual in the cohort fit this profile, his case is instructive when compared to the remainder of patients with hyperemia-associated intracranial hypertension. He was distinctive among this group in having the fewest unfavorable factors on CT scan, a transient improvement in level of consciousness, and a favorable response to pentobarbital therapy. Additionally, while receiving high-dose pentobarbital, he exhibited the lowest cerebral metabolic rate for glucose recorded to date in our head-injured population, as imaged by fluorodeoxylglucose PET. Nordström, et al., 31 and Messeter, et al., 27 previously reported that a favorable response to barbiturate therapy was characterized by a significant decrease in CBF, cerebral metabolic rate of O 2 , and ICP. Vasoreactivity, as measured by PaCO 2 responsiveness, also correlated strongly with response to barbiturate therapy, in that patients with preserved PaCO 2 reactivity had a 75% favorable outcome when treated with barbiturates, whereas those with abolished PaCO 2 reactivity had only a 9% favorable outcome with barbiturate therapy. These findings indicate that metabolic suppressive therapy will be effective in controlling ICP in patients with preserved vasoreactivity. However, this subset of individuals appears to comprise a minority of patients with head injuries, and identifying them early in the course of injury remains problematic.
Hyperemia With Intracranial Hypertension and Poor Outcome (Vasoparalysis).
In stark contrast to the two groups just described are the seven remaining individuals in Group 1 with hyperemia-associated intracranial hypertension. The severe degree of primary brain injury as evidenced by low initial GCS scores and CT findings, the high incidence of hypotension, the protracted course of elevated ICP and hyperemia, as well as the uniformly poor response to metabolic suppressive therapy clearly distinguish these patients from the remainder of the cohort. Their clinical profile suggests that they sustained an overwhelming initial insult, with subsequent gross impairment of metabolic vasoreactivity and pressure autoregulation, a condition previously termed "vasoparalysis" by Langfitt, et al., 21 more than 30 years ago. Although impaired vasoreactivity was not specifically documented in the six patients in whom metabolic suppressive therapy failed, the presence of hyperemia and intracranial hypertension in the setting of metabolic suppressive therapy and vasopressor support in five of these patients substantiate this concept. Metabolic suppressive therapy appears destined to fail in the great majority of these patients, given the severity of injury and the fact that cerebral metabolism may already be profoundly depressed.
Whether there are viable treatment options for these patients is unclear. One approach advocated to control marked intracranial hypertension is to elevate CPP to optimize pressure autoregulation. 36 Although mean hourly CPP for patients in this group was 75 mm Hg, it averaged 65 mm Hg at the time of simultaneous hyperemia and high ICP. If CPP had been higher, it is possible that reflex vasoconstriction may have occurred, resulting in a favorable decrease in cerebral blood volume and ICP. Although this approach may be effective in many head-injured patients, we believe these individuals were, in general, maximally treated with volume expansion and vasopressors. Higher CPPs would likely have driven CBF and ICP even higher. Given that CBF was not measured in the recent report on CPP management by Rosner, et al., 36 one wonders what proportion of the 40% of patients with poor outcome had hyperemia-associated intracranial hypertension secondary to impaired vasoreactivity. Results from the present study indicate that such individuals may comprise 20% or more of patients with unfavorable outcome despite maximal medical and surgical management.
Intracranial Hypertension Without Hyperemia. In these individuals (Group 3) CBF remained in a subnormal range and probably contributed minimally to the development of raised ICP. Intracranial hypertension resulted presumably from focal mass lesions such as cerebral contusions and nonevacuated extraaxial collections, from cytotoxic, vasogenic, or pericontusional edema, and possibly from increases in cerebral blood volume. 5, 24, 28, 29 In support of this concept is the fact that 10 of 12 patients in this group had multiple contusions and six had evacuated hematomas, the highest incidence of these findings in all patient groups. Although the majority of these individuals had severe and prolonged bouts of intracranial hypertension, elevated ICP was generally responsive to mild hyperventilation, CSF drainage, mannitol, and sedative-hypnotic therapy. In only one of 12 individuals did conventional ICP therapy fail, necessitating treatment with high-dose barbiturates.
Normal ICP Without Hyperemia. This subset of patients (Group 4) comprised almost 46% of the entire cohort. It was distinctive in having the oldest patients, with 14 of 27 being 35 years of age or older. Additionally, this group had the highest incidence of patients with markedly depressed blood flow. The mean CBF was less than or equal to 33 ml/100 g/minute in 11 patients, of whom 10 had a poor outcome. In total, older age or low CBF was documented in 15 of 19 patients with a poor outcome. In four other patients with poor outcome, hypotensive episodes in two and an evacuated subdural hematoma in one were probably important factors. The deleterious impact of advanced age and low blood flow appear to explain best the overall poor outcome of this patient group. 8, 35, 42 It is unclear how neurological recovery might have been improved in more of these patients, particularly because intracranial hypertension was so unusual and CPP was generally maintained above 80 mm Hg.
Toward Further Defining Injury Subtypes. This study and the work of others such as Miller, et al., 29 and Nordström, et al., 31 indicate that there are relatively distinct subgroups of patients with head injuries who may be optimally treated with significantly divergent therapies. Although the present categorization scheme based on ICP, CBF, and response to treatment is preliminary, it provides a framework from which different treatment regimens can be tested. Additional investigations are needed to determine the relative contribution of CBF and cerebral blood volume in the development of intracranial hypertension. 5, 29 However, just as marked and frequent fluctuations in ICP are known to occur early after injury, so too are wide variations in CBF. 39 The temporal and regional variability in CBF makes determining its role in the evolution of intracranial hypertension difficult to ascertain, particularly when using xenon-133 or Xe-CT, which are typically performed only once per day. Modalities providing continuous measurement of CBF, or estimates of blood flow such as thermal diffusion flowmetry, transcranial Doppler, and jugular venous saturation monitoring may be more ideally suited to capturing these dynamic fluctuations and their relationship to ICP. 1, 12, 19, 39, 40 
Relationship of Vasopressor Therapy to CBF and ICP
This investigation found that ICP was significantly higher in CBF studies performed in patients receiving vasopressors than those performed in patients not receiving vasopressors. Additionally, a greater proportion of studies with hyperemia and intracranial hypertension were performed in patients receiving vasopressors than were studies of any other type. Although these data are only correlative, and sequential CBF and ICP measurements were not performed in patients receiving or not receiving vasopressors, these findings are in agreement with those of previous investigations. Bouma, et al., 7 demonstrated significant elevations in ICP secondary to vasopressorinduced increases in CPP and CBF, in patients with impaired pressure autoregulation. In a related report, Fortune, et al., 12 reported on 14 head-injured patients with 94 instances of persistently elevated ICP after endotracheal suctioning. This rise in ICP correlated directly with increases in blood pressure and jugular venous saturation. It was concluded that ICP spikes arose directly from increases in CBF secondary to impairment of pressure autoregulation. These studies and the present report indicate that impaired pressure autoregulation is relatively common after head injury and that elevations of blood pressure from vasopressors or physiological stimulation may result in passive and prolonged increases in CBF and ICP.
Conclusions
This investigation highlights the heterogeneous nature of the pathophysiology of traumatic brain injury, particularly regarding the etiology of intracranial hypertension and the significance of blood flow elevations in the acute postinjury period. It remains difficult, however, to distinguish between different types of injuries early in the clinical course, when specific therapeutic approaches are ideally instituted. Further studies addressing the metabolic derangements and alterations in vasoreactivity after head injury are warranted, particularly as they relate to fluxes in CBF and ICP. Finally, although it is certainly important to maintain adequate CPP to reduce the risk of posttraumatic ischemia and optimize autoregulatory function in patients with head injuries, this study emphasizes the need for the development of more targeted therapies in treating this diverse and challenging group of neurosurgical patients.
